Advocacy Update ~ July 16, 2018

This post was written by the GHC Advocacy Team.

Senate and House Appropriations Committees Release LHHS Bills
Both the Senate and House Appropriations committees marked up their respective Labor, Health and Human Services and Education bills (LHHS) for Fiscal Year (FY) 2019, which includes funding for global health programs at the Centers for Disease Control and Prevention (CDC) and the National Institutes of Health (NIH). It is possible that the LHHS bill will be rolled into a minibus, several appropriations bills bundled into one bill, although the timing of this is unknown.

Download the funding chart.

Highlights of the House LHHS bill
The House provided $178.9 billion overall for the bill. The CDC’s Center for Global Health received flat funding at $488.6 million, with Global Health Protection receiving $108.2 million. The National Center for Emerging Zoonotic and Infectious Disease (NCEZID), also within CDC, received a $52 million decrease ($562.6 million in comparison to $614.6 million in FY 2018). The Fogarty International Center at NIH received a slight increase of $634,000 ($76.6 million in comparison to $75.7 million in FY 2018). The National Institute of Allergy and Infectious Diseases (NIAID) also received a slight increase ($5.4 billion in comparison to $5.3 billion in FY 2018).

Highlights of the Senate LHHS bill
The Senate provided $1.1 trillion overall for the bill. In the Senate bill, CDC’s Center for Global Health is flat funded at $488.6 million, of which $108.2 million is for the Global Public Health Protection. NCEZID received a $3 million increase ($617.5 million in comparison to $614.5 million in FY 2018). The Fogarty International Center received a little over $2 million increase ($78.2 million in comparison to $75.7 million in FY 2018). NIAID received an increase of about $200 million ($5.5 billion in comparison to $5.3 billion in FY 2018).

House Foreign Affairs Committee Holds Hearing on TB
Last week, the Centers for Disease Control and Prevention (CDC), U.S. Agency for International Development (USAID), and the State Department testified in front of the House Foreign Affairs Committee on Tuberculosis (TB) in Southern Africa. Agency representatives provided updates on current TB programs and progress on interagency collaboration on the U.S. Global TB Strategy. Witnesses included: Ambassador Deborah L. Birx, U.S. Global AIDS Coordinator at the Department of State; Irene Koek, Senior Deputy Assistant Administrator of the Global Health Bureau at USAID; and Dr. Rebecca Martin, Director of the Center for Global Health at CDC.

The hearing focused on the importance of collaboration among the three agencies and across other global health sectors, specifically in regards to TB/HIV coinfection. Dr. Martin discussed how CDC collaborates with the State Department through the President’s Emergency Plan for AIDS Relief (PEPFAR) to test TB patients for HIV, and provide treatment for people living with HIV/TB coinfections. Ambassador Birx emphasized the need to improve the scale of TB preventive therapy to help lower TB prevalence and reduce HIV coinfection. Both Dr. Martin and Ms. Koek stated that having U.S. government leadership present at the upcoming UN High-Level Meeting on TB provides opportunities for new political commitments to end TB and accelerate progress where it is needed the most.

Congressmen Tom Garrett (R-VA) and Joaquin Castro (D-TX) spoke about their families’ experiences with TB and the importance of this work both in the U.S. and abroad. Chairman Christopher Smith (R-NJ) expressed interest in TB funding and the return on investment (ROI) TB-related programs yield. Congressman Garrett pushed further on the issue of funding, asking what he should tell his constituents regarding the ROI of TB-related programs. Dr. Martin responded, “Investments in TB are smart, as every U.S. dollar invested in TB yields $43 in return.”